EGFR and neoplasm: On the other hand, there was also synergy between antiangiogenic agents and immune checkpoint inhibitors, and antiangiogenic agents showed immunomodulatory effects (24), could improve the tumor microenvironment for immunosuppression in patients with EGFR mutations.